The drugs targeting the EGFR-RAS-ERK pathway, such as the anti-EGFR antibody drugs including cetuximab and panitumumab, have been prescribed as therapeutic drugs for patients with cancers such as metastatic CRC. This evidence concerns the gene EGFR and cancer.